PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer
Open Access
- 2 August 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (18) , 4696-4708
Abstract
Abnormalities in genetic and epigenetic modifications can lead to drastic changes in gene expression profiles that are associated with various cancer types. Small cell lung cancer (SCLC) is an aggressive and deadly form of lung cancer with limited effective therapies currently available. By utilizing a genome-wide CRISPR-Cas9 dropout screen in SCLC cells, we identified paired box protein 9 (PAX9) as an essential factor that is overexpressed in human malignant SCLC tumor samples and is transcriptionally driven by the BAP1/ASXL3/BRD4 epigenetic axis. Genome-wide studies revealed that PAX9 occupies distal enhancer elements and represses gene expression by restricting enhancer activity. In multiple SCLC cell lines, genetic depletion of PAX9 led to significant induction of a primed-active enhancer transition, resulting in increased expression of a large number of neural differentiation and tumor-suppressive genes. Mechanistically, PAX9 interacted and cofunctioned with the nucleosome remodeling and deacetylase (NuRD) complex at enhancers to repress nearby gene expression, which was reversed by pharmacologic HDAC inhibition. Overall, this study provides mechanistic insight into the oncogenic function of the PAX9/NuRD complex epigenetic axis in human SCLC and suggests that reactivation of primed enhancers may have potential therapeutic efficacy in treating SCLC expressing high levels of PAX9.Significance: A genome-wide screen in small cell lung cancer reveals PAX9/NuRD-mediated epigenetic enhancer silencing and tumor progression, supporting the development of novel personalized therapeutic approaches targeting the PAX9-regulated network.Keywords
All Related Versions
Funding Information
- National Heart, Lung, and Blood Institute (R01HL149883)
- National Heart, Lung, and Blood Institute (R01HL153122)
- National Cancer Institute (P30 CA060553)
- NIH Office of the Director (S10OD025194)
This publication has 51 references indexed in Scilit:
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsPLOS ONE, 2013
- A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targetsGenes & Development, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010
- Histone H3K27ac separates active from poised enhancers and predicts developmental stateProceedings of the National Academy of Sciences, 2010
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)Journal of Thoracic Oncology, 2010
- Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung CarcinomaCancer Research, 2010
- Key Genes in Lung Cancer Translational Research: A Meta-AnalysisPathobiology, 2010
- Characterizing the developmental pathways TTF-1 , NKX2–8 , and PAX9 in lung cancerProceedings of the National Academy of Sciences, 2009
- Histone modifications at human enhancers reflect global cell-type-specific gene expressionNature, 2009
- Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancerProceedings of the National Academy of Sciences, 2007